Table of Contents Author Guidelines Submit a Manuscript
Biochemistry Research International
Volume 2018, Article ID 7463796, 5 pages
https://doi.org/10.1155/2018/7463796
Research Article

Assessment of Salivary Adipokines Resistin, Visfatin, and Ghrelin as Type 2 Diabetes Mellitus Biomarkers

1Departments of Oral Pathology, Medicine and Radiology, Indiana University School of Dentistry, Indianapolis, IN, USA
2Preventive and Community Dentistry, Indiana University School of Dentistry, Indianapolis, IN, USA

Correspondence should be addressed to Mythily Srinivasan; ude.ui@vinirsym

Received 17 August 2017; Accepted 31 October 2017; Published 1 February 2018

Academic Editor: Paul W. Huber

Copyright © 2018 Mythily Srinivasan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization (WHO), Global Report on Diabetes, WHO Press, Geneva, Switzerland, 2016.
  2. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Rodger, “Non-insulin-dependent (type II) diabetes mellitus,” Canadian Medical Association Journal, vol. 145, no. 12, pp. 1571–1581, 1991. View at Google Scholar
  4. K. Færch, K. Borch-Johnsen, J. J. Holst, and A. Vaag, “Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?” Diabetologia, vol. 52, no. 9, pp. 1714–1723, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Sattar, “Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities,” Diabetic Medicine, vol. 29, no. 1, pp. 5–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. P. N. Surampudi, J. John-Kalarickal, and V. A. Fonseca, “Emerging concepts in the pathophysiology of type 2 diabetes mellitus,” Mount Sinai Journal of Medicine, vol. 76, no. 3, pp. 216–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Kolberg, T. Jorgensen, R. W. Gerwien et al., “Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort,” Diabetes Care, vol. 32, no. 7, pp. 1207–1212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Wu, Z. Yu, Q. Qi, H. Li, Q. Sun, and X. Lin, “Joint analysis of multiple biomarkers for identifying type 2 diabetes in middle-aged and older Chinese: a cross-sectional study,” BMJ Open, vol. 1, no. 1, p. e000191, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Rabe, M. Lehrke, K. G. Parhofer, and U. C. Broedl, “Adipokines and insulin resistance,” Molecular Medicine, vol. 14, no. 11-12, pp. 741–751, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. J. Dunmore and J. E. Brown, “The role of adipokines in beta-cell failure of type 2 diabetes,” Journal of Endocrinology, vol. 216, no. 1, pp. T37–T45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. S. J. Kim, C. Nian, and C. H. McIntosh, “Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes,” Journal of Biological Chemistry, vol. 282, no. 47, pp. 34139–34134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. D. G. Haider, G. Schaller, S. Kapiotis, C. Maier, A. Luger, and M. Wolzt, “The release of the adipocytokine visfatin is regulated by glucose and insulin,” Diabetologia, vol. 49, no. 8, pp. 1909–1914, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Stofkova, “Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity,” Endocrine Regulations, vol. 44, no. 1, pp. 25–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Collden, M. H. Tschop, and T. D. Muller, “Therapeutic potential of targeting the ghrelin pathway,” International Journal of Molecular Sciences, vol. 18, no. 4, p. 798, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Dezaki, H. Sone, and T. Yada, “Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis,” Pharmacology and Therapeutics, vol. 118, no. 2, pp. 239–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Hasegawa, M. Ohta, Y. Ichida et al., “Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity,” Acta Diabetologica, vol. 42, no. 2, pp. 104–109, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Osawa, M. Ochi, Y. Tabara et al., “Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes,” Clinical Endocrinology, vol. 69, no. 1, pp. 74–80, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Li, G. Yang, Q. Li et al., “Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects,” Experimental and Clinical Endocrinology and Diabetes, vol. 114, no. 10, pp. 544–548, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Katsuki, H. Urakawa, E. C. Gabazza et al., “Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus,” European Journal of Endocrinology, vol. 151, no. 5, pp. 573–577, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Sharifi, M. Yamini, A. Esmaeilzadeh, N. Mousavinasab, and Z. Shajari, “Acylated ghrelin and leptin concentrations in patients with type 2 diabetes mellitus, people with prediabetes and first degree relatives of patients with diabetes, a comparative study,” Journal of Diabetes and Metabolic Disorders, vol. 12, no. 1, p. 51, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Ueno, T. Shiiya, M. Mizuta, S. M. Mondal, and M. Nakazato, “Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics,” Endocrine Journal, vol. 54, no. 6, pp. 895–902, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Akin, M. Bastemir, E. Alkis, and B. Kaptanoglu, “SHBG levels correlate with insulin resistance in postmenopausal women,” European Journal of Internal Medicine, vol. 20, no. 2, pp. 162–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. H. Price, C. J. Weir, P. Welsh et al., “Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk prediction in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study,” Atherosclerosis, vol. 264, pp. 67–73, 2017. View at Publisher · View at Google Scholar
  24. P. V. Rao, A. P. Reddy, X. Lu et al., “Proteomic identification of salivary biomarkers of type-2 diabetes,” Journal of Proteome Research, vol. 8, no. 1, pp. 239–245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Amado, M. J. Lobo, P. Domingues, J. A. Duarte, and R. Vitorino, “Salivary peptidomics,” Expert Review of Proteomics, vol. 7, no. 5, pp. 709–721, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Loo, W. Yan, P. Ramachandran, and D. T. Wong, “Comparative human salivary and plasma proteomes,” Journal of Dental Research, vol. 89, no. 10, pp. 1016–1023, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Conner, B. Iranpour, and J. Mills, “Alteration in parotid salivary flow in diabetes mellitus,” Oral Surgery, Oral Medicine, Oral Pathology, vol. 30, no. 1, pp. 55–59, 1970. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Jurysta, N. Bulur, B. Oguzhan et al., “Salivary glucose concentration and excretion in normal and diabetic subjects,” Journal of Biomedicine and Biotechnology, vol. 2009, Article ID 430426, 6 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Gupta, S. V. Sandhu, H. Bansal, and D. Sharma, “Comparison of salivary and serum glucose levels in diabetic patients,” Journal of Diabetes Science and Technology, vol. 9, no. 1, pp. 91–96, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Marchetti, L. Benzi, A. Masoni et al., “Salivary insulin concentrations in type 2 (non-insulin-dependent) diabetic patients and obese non-diabetic subjects: relationship to changes in plasma insulin levels after an oral glucose load,” Diabetologia, vol. 29, no. 10, pp. 695–698, 1986. View at Publisher · View at Google Scholar · View at Scopus
  31. A. C. Vasconcelos, M. S. Soares, P. C. Almeida, and T. C. Soares, “Comparative study of the concentration of salivary and blood glucose in type 2 diabetic patients,” Journal of Oral Science, vol. 52, no. 2, pp. 293–298, 2010. View at Publisher · View at Google Scholar
  32. B. Wang, J. Du, Z. Zhu, Z. Ma, S. Wang, and Z. Shan, “Evaluation of parotid salivary glucose level for clinical diagnosis and monitoring type 2 diabetes mellitus patients,” BioMed Research International, vol. 2017, Article ID 2569707, 5 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Zhang, H. Xiao, S. Karlan et al., “Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer,” PLoS One, vol. 5, no. 12, Article ID e15573, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Srinivasan, K. N. Kodumudi, and S. L. Zunt, “Soluble CD14 and toll-like receptor-2 are potential salivary biomarkers for oral lichen planus and burning mouth syndrome,” Clinical Immunology, vol. 126, no. 1, pp. 31–37, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Janardhanam, S. Zunt, and M. Srinivasan, “Quality assessment of saliva bank samples,” Biopreservation and Biobanking, vol. 10, no. 3, pp. 282–287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Prakasam and M. Srinivasan, “Evaluation of salivary biomarker profiles following non-surgical management of chronic periodontitis,” Oral Diseases, vol. 20, no. 2, pp. 171–177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. K. J. Lipska and H. M. Krumholz, “Is hemoglobin A1c the right outcome for studies of diabetes?” JAMA, vol. 317, no. 10, pp. 1017-1018, 2017. View at Publisher · View at Google Scholar · View at Scopus
  38. P. P. Costa, G. L. Trevisan, G. O. Macedo et al., “Salivary interleukin-6, matrix metalloproteinase-8, and osteoprotegerin in patients with periodontitis and diabetes,” Journal of Periodontology, vol. 81, no. 3, pp. 384–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. J. B. Meigs, “Multiple biomarker prediction of type 2 diabetes,” Diabetes Care, vol. 32, no. 7, pp. 1346–1348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Williamson, C. Munro, R. Pickler, M. J. Grap, and R. K. Elswick Jr., “Comparison of biomarkers in blood and saliva in healthy adults,” Nursing Research and Practice, vol. 2012, Article ID 246178, 4 pages, 2012. View at Publisher · View at Google Scholar
  41. C. M. Kusminski, P. G. McTernan, and S. Kumar, “Role of resistin in obesity, insulin resistance and Type II diabetes,” Clinical Science, vol. 109, no. 3, pp. 243–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. A. R. Pradeep, N. M. Raghavendra, A. Sharma et al., “Association of serum and crevicular visfatin levels in periodontal health and disease with type 2 diabetes mellitus,” Journal of Periodontology, vol. 83, no. 5, pp. 629–634, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. G. S. Desai and S. T. Mathews, “Saliva as a non-invasive diagnostic tool for inflammation and insulin-resistance,” World Journal of Diabetes, vol. 5, no. 6, pp. 730–738, 2014. View at Publisher · View at Google Scholar
  44. I. Mamali, N. D. Roupas, A. K. Armeni, A. Theodoropoulou, K. B. Markou, and N. A. Georgopoulos, “Measurement of salivary resistin, visfatin and adiponectin levels,” Peptides, vol. 33, no. 1, pp. 120–124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Yin, H. Gao, J. Yang, L. Xu, and M. Li, “Measurement of salivary resistin level in patients with type 2 diabetes,” International Journal of Endocrinology, vol. 2012, Article ID 359724, 5 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. N. N. Rudovich, V. J. Nikiforova, B. Otto et al., “Metabolomic linkage reveals functional interaction between glucose-dependent insulinotropic polypeptide and ghrelin in humans,” American Journal of Physiology: Endocrinology and Metabolism, vol. 301, no. 4, pp. E608–E617, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Aydin, “A comparison of ghrelin, glucose, alpha-amylase and protein levels in saliva from diabetics,” Journal of Biochemistry and Molecular Biology, vol. 40, no. 1, pp. 29–35, 2007. View at Publisher · View at Google Scholar
  48. A. Hulman, R. K. Simmons, E. J. Brunner et al., “Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study,” Diabetologia, vol. 60, no. 7, pp. 1252–1260, 2017. View at Publisher · View at Google Scholar · View at Scopus
  49. A. G. Tabak, M. Jokela, T. N. Akbaraly, E. J. Brunner, M. Kivimaki, and D. R. Witte, “Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study,” The Lancet, vol. 373, no. 9682, pp. 2215–2221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Spielmann and D. Wong, “Saliva: diagnostics and therapeutic perspectives,” Oral Diseases, vol. 17, no. 4, pp. 345–354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Rathnayake, S. Akerman, B. Klinge et al., “Salivary biomarkers for detection of systemic diseases,” PLoS One, vol. 8, no. 4, Article ID e61356, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Srinivasan, C. Blackburn, M. Mohamed, A. V. Sivagami, and J. Blum, “Literature-based discovery of salivary biomarkers for type 2 diabetes mellitus,” Biomarker Insights, vol. 10, pp. 39–45, 2015. View at Publisher · View at Google Scholar · View at Scopus